Tiziana Life Sciences remains a pre-revenue biotechnology entity entirely dependent on external financing to sustain its intranasal Foralumab clinical pipeline. The company faces significant solvency risks as its equity base has eroded to a nominal $52.0K, nec...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 18, 2026 | -$0.08+0.0% vs -$0.08 | — vs — |
Q2 2026 May 1, 2026 | -$0.22-143.0% vs -$0.09 | — vs — |
Q4 2025 Oct 3, 2025 | -$0.10-35.4% vs -$0.07 | — vs — |
Q3 2025 Jul 8, 2025 | -$0.06 vs — | — vs — |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The randomized, double-blind, placebo-controlled INFORM-MS trial enrolled 48 patients across three cohorts at multiple leading U.S.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to study its intranasal foralumab in combination with anti-CD20 therapy for multiple sclerosis patients. The planned trial will target relapsing-remitting multiple sclerosis (RRMS) patients who respond poorly to anti-CD20 therapy alone, a shortfall that may stem from untreated neuroinflammation.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment for neurodegenerative disease. The clinical-stage company is developing foralumab, an anti-CD3 antibody delivered via nasal spray, to stimulate regulatory T-cell (Treg) production and reduce the inflammatory processes that drive neurodegeneration.
3:40pm: Small cap wrap Tiziana Life Sciences Ltd (NASDAQ:TLSA) received a Buy rating and $7 price target from BTIG, which highlighted its nasal anti-CD3...
Benchmark TLSA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Tiziana Life Sciences Ltd (TLSA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.89 | $56.62M | -2.78 | — | — | -924.32% | — | |
| $37.29 | $7.7B | -13.46 | — | -7585.86% | -69.59% | — | |
| $14.38 | $408.72M | -5.99 | -51.43% | -391.9% | -46.54% | — | |
| $300.65 | $8.38B | -22.30 | -100% | — | -34.15% | — | |
| $122.06 | $10.04B | -33.08 | -16.72% | -285.41% | -21.5% | — | |
| $26.87 | $3.38B | -8.17 | -4.26% | -386.32% | -87.98% | — |
Tiziana Life Sciences Ltd (TLSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when TLSA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tiziana Life Sciences Ltd (TLSA) stock FAQ — growth, dividends, profitability & financials explained
Tiziana Life Sciences Ltd (TLSA) reported a net loss of $34.9M for fiscal year 2025.
Tiziana Life Sciences Ltd (TLSA) has a return on equity (ROE) of -924.3%. Negative ROE indicates the company is unprofitable.
Tiziana Life Sciences Ltd (TLSA) had negative free cash flow of $14.1M in fiscal year 2025, likely due to heavy capital investments.
